The PANNA study aims to collect pharmacokinetic data in HIV infected pregnant women. In the PANNA network the first aim is to study newly developed ARVs of which no or limited PK data during pregnancy are available. Visit the PANNA website.
What is PANNA?
Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation
The PANNA network is made of 17 centres across 7 European countries. It was initiated by David Burger at the Radboud University Nijmegen Medical Centre in the Netherlands, and it is coordinated by Angela Colbers. Currently the PANNA network focuses on collecting much needed pharmacokinetic data on newly developed antiretroviral drugs during pregnancy in European populations, but could also collect these data for other antiviral compounds such as those for use against hepatitis C.
Why is PANNA needed?
Physiological changes take place in pregnancy, which can influence the PK of antiretrovirals and might lead to decreased drug exposure. As the changes in pharmacokinetics during pregnancy are most prominent in the third trimester, an investigative study into this population is needed to ensure that adequate drugs are developed.
What is PANNA’s goal?
The PANNA study aims to collect pharmacokinetic data in HIV infected pregnant women, using newly developed antiretroviral agents for which no or only limited pharmacokinetic data are available. The study team is collecting pharmacokinetic curves in the 3rd trimester of pregnancy and at 4-6 weeks post-partum. Cord blood will also be collected during delivery to assess the placental passage of the antiretroviral drugs
This study is funded by Penta. Additional support is provided by NEAT, Merck, BMS, Janssen and CTN.